What question did this study set out to answer?

To evaluate the effectiveness of combination chemotherapy and immunotherapy in improving survival for metastatic gastroenteropancreatic neuroendocrine carcinomas.

April 15, 2026Open Access

Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas

Key Points

To evaluate the effectiveness of combination chemotherapy and immunotherapy in improving survival for metastatic gastroenteropancreatic neuroendocrine carcinomas.
Comparison of outcomes using combination chemoIO against chemotherapy alone.
Analysis based on ongoing clinical trials.
Focus on metastatic gastroenteropancreatic neuroendocrine carcinomas.
Combination chemoIO likely leads to improved survival compared to chemotherapy alone.
Results from ongoing trials may influence clinical practices in treating these cancers.

Abstract

Combination chemoIO may improve survival in metastatic GEP-NECs as compared to chemotherapy alone. Results of currently ongoing clinical trials exploring the role of immunotherapy in extrapulmonary NECs may help guide clinical practice in GEP-NECs.

Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas

Key Points

Abstract

Cite This Study